MammoScreen®
Therapixel
Product specifications |
Information source:
Vendor
Last updated: May 29, 2022 |
General | |
---|---|
Product name | MammoScreen® |
Company | Therapixel |
Subspeciality | Breast |
Modality | Mammography |
Disease targeted | Breast cancer |
Key-features | Lesion detection and characterization, level-of-suspicion score |
Suggested use | During: perception aid (prompting all abnormalities/results/heatmaps) |
Data characteristics | |
Population | Screening mammography |
Input | Screening DBT & FFDM, prior images if available |
Input format | DICOM |
Output | Visual report with detected and assessed lesions |
Output format | Web interface or DICOM SC or DICOM SR. |
Technology | |
Integration | Integration via AI marketplace or distribution platform, Stand-alone webbased |
Deployment | Cloud-based |
Trigger for analysis | Automatically, right after the image acquisition |
Processing time | |
Certification | |
CE
|
Certified,
Class IIa
, MDD
|
FDA
|
510(k) cleared, Class II |
Market presence | |
On market since | FFDM FDA 05-2020 FFDM CE 12-2020 DBT CE 11-2021 DBT FDA 11-2021 |
Distribution channels | Ferrum Health, Softway Medical, others on demand |
Countries present (clinical, non-research use) | |
Paying clinical customers (institutes) | |
Research/test users (institutes) | |
Pricing | |
Pricing model | Subscription |
Based on | |
Evidence | |
Peer reviewed papers on performance | |
Non-peer reviewed papers on performance |
|
Other relevant papers |